Trials / Completed
CompletedNCT01407003
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
A Randomized, Double-blind, Placebo-controlled, 4-part, Interwoven Single- and Multiple-ascending Dose Study to Assess Safety, Tolerability, PK and PD of LIK066 in Healthy Subjects and in Patients With T2DM
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will assess safety, tolerability, and effect of LIK066 on blood glucose in healthy subjects and in patients with T2DM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LIK066 | Participants will receive a single or multiple doses of LIK066 |
| DRUG | Placebo | Participants will receive a single or multiple doses of a matching placebo |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2011-08-01
- Last updated
- 2020-12-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01407003. Inclusion in this directory is not an endorsement.